DUBLIN–(BUSINESS WIRE)–The “Companion Diagnostic Markets – the Future of Diagnostics by Application, Technology and Funding With Executive and Consultant Guides 2023-2027” report has been added to ResearchAndMarkets.com’s offering.
The diagnostics industry is undergoing a significant transformation with the rapid advancement of Companion Diagnostics, especially within oncology, a sector witnessing the adoption of immune-oncology practices. This emerging market is transitioning from the laboratory to clinical settings, with regulatory bodies such as the FDA fostering a conducive environment for this diagnostic technology’s growth.
Understanding the Growth of Personalized Companion Diagnostics
Research on Personalized Companion Diagnostics indicates a trend toward customization in patient care, significantly impacting the future of diagnostics. Diagnostic manufacturers and pharmaceutical companies are actively collaborating to establish new and substantial business opportunities.
Innovations in Diagnostic Technology and Market Dynamics
The landscape is marked by rapid advancements in scientific knowledge and technology, with molecular diagnostics seeing a reduction in costs. This shift is encouraging companies to invest strategically to capitalize on the surge of new testing paradigms and technology trends.
Strategic Forecasting for Growth and Demand
- Existing laboratories and hospitals can leverage the forecast data for planning and expanding clinical facilities.
- Professionals are provided with guidance to fully utilize the analytical data offered in the publication.
Global Insights and Localized Data
Further enriching the report is a detailed breakout for 18 countries and 4 regions, providing both global perspectives and localized data – a testament to the report’s comprehensive and adaptable nature.
Anticipating the Future of Diagnostics
The future of diagnostics heralds a period of innovative, tailored solutions that elevate patient care to new heights. The report concludes with an insightful year-long market forecast, equipping industry participants with the knowledge to navigate and excel in this evolving landscape.
For individuals and organizations seeking to understand the significant shifts and future outlook of the Companion Diagnostic market, this report serves as an indispensable tool, packed with data that can drive strategic decision-making and research investment choices, setting the stage for the next era of diagnostics.
Market Trends
Factors Driving Growth
- Level of Care.
- Immuno-oncology.
- Liability.
- The Aging World
- Factors Limiting Growth
- State of knowledge.
- Genetic Blizzard.
- Protocol Resistance.
- Regulation and coverage.
Instrumentation, Automation and Diagnostic Trends
- Traditional Automation and Centralization
- The New Automation, Decentralization and Point Of Care
- Instruments Key to Market Share
- Bioinformatics Plays a Role
- PCR Takes Command
- Next Generation Sequencing Fuels a Revolution
- NGS Impact on Pricing
- Whole Genome Sequencing, A Brave New World
- Companion Diagnostics Blurs Diagnosis and Treatment
- Shifting Role of Diagnostics
Companies Mentioned
- Abbott Laboratories
- AccuraGen Inc.
- Adaptive Biotechnologies
- Aethlon Medical
- Agilent/Dako
- Anchor Dx
- ANGLE plc
- ARUP Laboratories
- AVIVA Systems Biology
- Baylor Miraca Genetics Laboratories
- Beckman Coulter Diagnostics
- Becton, Dickinson and Company
- BGI Genomics Co. Ltd
- Bioarray Genetics
- Biocartis
- Biocept, Inc.
- Biodesix Inc.
- BioFluidica
- BioGenex
- BioIVT
- Biolidics Ltd
- bioMérieux Diagnostics
- Bioneer Corporation
- Bio-Rad Laboratories, Inc
- Bio-Reference Laboratories
- Bio-Techne
- Bioview
- Bolidics
- Boreal Genomics
- Bristol-Myers Squibb
- Burning Rock
- Cardiff Oncology
- Caris Molecular Diagnostics
- Castle Biosciences, Inc.
- CellCarta
- CellMax Life
- Cepheid (Danaher)
- Charles River Laboratories
- Circulogene
- Cizzle Biotech
- Clinical Genomics
- Cytolumina Technologies Corp.
- Datar Cancer Genetics Limited
- Diagnologix LLC
- Diasorin S.p.A.
- Dxcover
- Element Biosciences
- Enzo Biochem
- Epic Sciences
- Epigenomics AG
- Eurofins Scientific
- Fabric Genomics
- Fluxion Biosciences
- Freenome
- FUJIFILM Wako Diagnostics
- Fyr Diagnostics
- GeneFirst Ltd.
- Genetron Holdings
- GenomOncology
- GILUPI Nanomedizin
- Guardant Health
- HansaBiomed
- HeiScreen
- Helomics
- HTG Molecular Diagnostics
- iCellate
- Illumina
- Incell Dx
- Inivata
- INOVIQ
- Integrated Diagnostics
- Invitae Corporation
- Invivogen
- Invivoscribe
- Janssen Diagnostics
- Lunglife AI Inc
- MDNA Life SCIENCES, Inc.
- MDx Health
- Menarini Silicon Biosystems
- Mesa Laboratories, Inc.
- Millipore Sigma
- Miltenyi Biotec
- miR Scientific
- Myriad Genetics/Myriad RBM
- NantHealth, Inc.
- Natera
- NeoGenomics
- NGeneBio
- Novogene Bioinformatics Technology Co., Ltd.
- Oncocyte
- OncoDNA
- Ortho Clinical Diagnostics
- Oxford Nanopore Technologies
- PamGene
- Panagene
- Perkin Elmer (Revvity)
- Personal Genome Diagnostics
- Personalis
- Precipio
- Precision Medicine Group
- PrecisionMed
- Predicine
- Promega
- Qiagen
- Rarecells SAS
- RareCyte
- Roche Molecular Diagnostics
- Screencell
- Sema Holdings
- Sense Biodetection
- Siemens Healthineers
- simfo GmbH
- Singlera Genomics Inc.
- Singular Genomics
- Singulomics
- SkylineDx
- Standard BioTools
- Stilla Technologies
- Sysmex Inostics
- Tempus Labs, Inc.
- Thermo Fisher Scientific Inc.
- Todos Medical
- Ultima Genomics
- Veracyte
- Volition
- Vortex Biosciences
- Vyant Bio
For more information about this report visit https://www.researchandmarkets.com/r/iz1bkb
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900